CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Rachel E SanbornOmid HamidElisabeth Ge de VriesPatrick A OttJavier Garcia-CorbachoValentina BoniJohanna BendellKaren A AutioDaniel C ChoRuth PlummerMark StrohLawrence LuFiona ThistlethwaitePublished in: Journal for immunotherapy of cancer (2022)
The MTD and recommended phase 2 dose of pacmilimab (10 mg/kg)+ipilimumab (3 mg/kg) every 3 weeks is active and has a favorable tolerability profile.